- Home
- INV vs CVRX Comparison
INV vs CVRX Comparison
Compare INV & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- CVRX
- Stock Information
- Founded
- INV 2015
- CVRX 2000
- Country
- INV United States
- CVRX United States
- Employees
- INV N/A
- CVRX N/A
- Industry
- INV
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- INV
- CVRX Health Care
- Exchange
- INV NYSE
- CVRX Nasdaq
- Market Cap
- INV 173.3M
- CVRX 202.8M
- IPO Year
- INV N/A
- CVRX 2021
- Fundamental
- Price
- INV $4.86
- CVRX $6.34
- Analyst Decision
- INV Strong Buy
- CVRX Buy
- Analyst Count
- INV 2
- CVRX 7
- Target Price
- INV $14.00
- CVRX $14.50
- AVG Volume (30 Days)
- INV 58.5K
- CVRX 531.3K
- Earning Date
- INV 05-15-2025
- CVRX 05-08-2025
- Dividend Yield
- INV N/A
- CVRX N/A
- EPS Growth
- INV N/A
- CVRX N/A
- EPS
- INV N/A
- CVRX N/A
- Revenue
- INV $1,220,000.00
- CVRX $52,870,000.00
- Revenue This Year
- INV $1,336.39
- CVRX $13.92
- Revenue Next Year
- INV $204.86
- CVRX $19.89
- P/E Ratio
- INV N/A
- CVRX N/A
- Revenue Growth
- INV 18.27
- CVRX 25.62
- 52 Week Low
- INV $3.00
- CVRX $5.81
- 52 Week High
- INV $18.75
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- INV N/A
- CVRX 43.30
- Support Level
- INV N/A
- CVRX $4.30
- Resistance Level
- INV N/A
- CVRX $7.91
- Average True Range (ATR)
- INV 0.00
- CVRX 0.59
- MACD
- INV 0.00
- CVRX 0.07
- Stochastic Oscillator
- INV 0.00
- CVRX 51.27
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.